|Videos|November 3, 2022
Systemic Therapy in the Treatment of Non-Clear Cell RCC: The Evolving Landscape
Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC
3
NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC
4
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
5